HVTN 805/HPTN 093

Antiretroviral analytical treatment interruption (ATI) to assess immunologic and virologic responses in participants who initiated ART in early HIV infection after having received VRC01 or placebo in HVTN 703/HPTN 081.

Rationale

Antiretroviral therapy (ART) has greatly improved the health and quality of life for many people with HIV by suppressing the virus in their blood. However, this treatment can have long-term side effects and challenges, such as toxicity, drug interactions, stigma, and resistance. Therefore, researchers are looking for alternative approaches to control HIV without ART. One approach is to find ways to stop or manage HIV replication and reservoirs without relying on ART. Broadly neutralizing monoclonal antibodies (bnAbs) against HIV that are already present at the time of HIV acquisition may aid in boosting the immune system’s ability to support ART-free control.

Investigators

• Dr Carrie-Anne Mathew, IOR
• Prof Sinead Delany-Moretlwe, Sub Investigator
• Dr Elizabeth Roos, Sub Investigator
• Dr Nicole Poovan, Sub Investigator

Latest Update

April 2024

For more details about the HVTN 805/HPTN 093 study please email rhicomms@wrhi.ac.za